Azithromycin controlled-release microspheres - Pfizer

Drug Profile

Azithromycin controlled-release microspheres - Pfizer

Alternative Names: Azithromycin dihydrate microspheres for oral suspension - Pfizer; Azithromycin extended release - Pfizer; Azithromycin SR (2g single dose) - Pfizer; Sustained-release azithromycin - Pfizer; Zmax; Zmax for oral suspension; Zmax SR

Latest Information Update: 12 Aug 2015

Price : $50

At a glance

  • Originator Pfizer
  • Class Antibacterials; Eye disorder therapies; Macrolides; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute exacerbations of chronic bronchitis; Acute sinusitis; Community-acquired pneumonia; Pharyngitis; Respiratory tract infections; Tonsillitis
  • Discontinued Otitis media

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 12 Aug 2015 No recent reports on development identified - Phase-III for Community-acquired pneumonia in Japan (PO)
  • 29 Oct 2010 Launched for Acute exacerbations of chronic bronchitis in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top